Clinical Trial Update: A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing second-line FOLFIRI ± bevacizumab versus irinotecan ± bevacizumab in metastatic colorectal cancer; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms
• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Intestinal Neoplasms
• Neoplasm Metastasis

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Neoplasms, Neoplasm Metastasis | Phase 3 | Status: UNKNOWN